If your brand has attracted only mockery and mirth then simply change the name of your brand so that bad vibes about it disappear. This appears to be the marketing strategy adopted by AstraZeneca, whose vaccines should be labelled with the skull and crossbones.

Beware; AstraZeneca has rechristened its Covid-19 vaccine, a move that coincides with the company’s struggle to reassure the public that its drug is safe, following numerous reports of potential adverse effects.

The British-Swedish pharmaceutical has rebranded its jab, which previously went by the simple AstraZeneca Covid-19 Vaccine, to Vaxzevria. But, horrifyingly, the name change is the only change in the malignant and notorious so-called AstraZeneca anti-Covid vaccine.

In a press release, the company said that the name change does not involve any alterations to the actual drug. Medical workers should be made aware of the rebrand. The cunning bastards have given the labeling and appearance a makeover in the hope that no one will notice. The firm heavily invested in by the political and ruling caste said the labelling and packaging can look different. 

The European Medicines Agency signed off on the new name last week after AstraZeneca sought approval for the change from the EU regulator. Covishield, which is based on the same formula but was developed in collaboration with the Serum Institute of India will retain its current branding.

The debut of Vaxzevria comes as AstraZeneca fends off growing unease and uncertainty about its drug, which was created in tandem with Oxford University.

More than a dozen countries across Europe have temporarily halted their rollout of the vaccine following reports of blood clots. EU health officials, as well as the pharma firm, have maintained that the vaccine is safe and not related to the medical episodes, some of which led to death.

On Monday, Canada joined the growing list of countries that have suspended or placed restrictions on the drug’s use. Citing potential safety concerns, the country said that the vaccine would not be administered to people younger than 55. 

The company was hit with more bad press after US regulators raised concerns that trial data used to gauge the efficacy of the vaccine was potentially out-dated and misleading. AstraZeneca said that it was working to update and verify the trial’s findings. The vaccine has not yet been approved for emergency use in the United States.

Despite reassurances from the medical bodies and governments, Europeans appear to be growing increasingly distrustful of the AstraZeneca drug and indeed all heavily-promoted government-sponsored cdrugs. A poll released by YouGov last Monday revealed that only 23% of French people and 32% of Germans consider the vaccine to be safe.  Source